Margetuximab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Margetuximab. Educational only — not medical advice.
Labeled uses
MARGENZA is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease [see Dosage and Administration (2.1) and Clinical Studies (14.1) ].
Source: FDA labeling via NIH DailyMed (set e97a5872…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.